

COMPANY ANNOUNCEMENT

Prima's final Phase IIa results accepted for poster presentation at US oncology meeting

1 May 2007, Melbourne, Australia: Prima BioMed Limited (ASX:PRR) today announced that final data from its Phase IIa trial of CVac™ in advanced ovarian cancer have been accepted for a poster discussion at the 2007 Annual Meeting of the American Society of Clinical Oncology (ASCO). The meeting will take place in Chicago, Illinois, June 1-5, 2007.

The poster presentation is titled:

Abstract ID 30962: 'Durable clinical responses in patients with ovarian carcinoma treated on a phase II trial of autologous dendritic cells pulsed with MUC1'.

"We are very pleased that the abstract has been accepted at this prestigious meeting representing our first opportunity to present the results internationally", stated Mr Eugene Kopp, CEO. "Now that Prima holds worldwide commercialisation rights for CVac™ and is aligning its clinical development program to international requirements, ASCO provides an excellent forum to generate international interest".

The information presented in the poster will also be discussed by a leading authority in Ovarian Cancer. The ASCO Annual Meeting is considered the premier educational and scientific event in the oncology community, attracting more than 29,000 attendees from all over the world in 2006.

For further information:

Company Contacts:

Company Enquiries	Eugene Kopp	03 9854 5700
Media Enquiries	Rebecca Wilson	0417 382 391

About Prima BioMed Limited

Prima BioMed (ASX: PRR) is a biotechnology company based in Melbourne, Australia. The company is focused on technologies in the fields of immunology and cancer immunotherapy, in particular on development of a dendritic-cell based immunotherapy targeting tumours expressing the Mucin-1 tumour antigen. Prima's lead product, CVac™ has completed Phase IIa clinical development in ovarian cancer.

About ASCO

The American Society of Clinical Oncology (ASCO) is a non-profit organization, founded in 1964, with overarching goals of improving cancer care and prevention and ensuring that all patients with cancer receive care of the highest quality. Nearly 25,000 oncology practitioners belong to ASCO, representing all oncology disciplines (medical, radiologic, and surgical oncology) and subspecialties. Members include physicians and

health-care professionals participating in approved oncology training programs, oncology nurses, and other practitioners with a predominant interest in oncology.

As the world's leading professional organization representing physicians who treat people with cancer, ASCO is committed to advancing the education of oncologists and other oncology professionals, to advocating for policies that provide access to high-quality cancer care, and to supporting the clinical trials system and the need for increased clinical and translational research

This press release contains forward-looking statements that are based on current management expectations. These statements may differ materially from actual future events or results due to certain risks and uncertainties, including without limitation, risks associated with drug development and manufacture, risks inherent in the extensive regulatory approval process mandated by the United States Food and Drug Administration and the Australian Therapeutic Goods Administration, delays in obtaining the necessary approvals for clinical testing, patient recruitment, delays in the conduct of clinical trials, future capitals needs, general economic conditions, and other risks and uncertainties detailed from time to time in the Company's filings with the Australian Stock Exchange.

Prima BioMed Ltd, Unit 7/79-83 High St, Kew VIC 3101, AUSTRALIA
Ph: +61 (0)3 9854 5700 Fax: +61 (0)3 9854 5777
www.primabiomed.com.au